Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Marius M. Hoeper(Medizinische Hochschule Hannover), Andrea Maria D’Armini(University of Pavia), Arno Fritsch(Bayer (United States)), Pavel Jansa(General University Hospital in Prague), Friedrich Grimminger(Justus-Liebig-Universität Gießen), Gerrit Weimann(Bayer (United States)), Martin R. Wilkins(Hammersmith Hospital), Gérald Simonneau(Inserm), D. Neuser(Bayer (United States)), Nick H. Kim(University of California San Diego), Eckhard Mayer(Kerckhoff Klinik)
Cited by 1,376
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k